Revolution Medicines Named Top Biotech Pick by BofA on Cancer Drug Approval

BofA Securities has named Revolution Medicines (RVMD) its top pick in the U.S. biotechnology sector, raising its price target for the company amid a broader industry rally and a key drug approval.

Rationale for the Upgrade

In a note to clients, BofA raised its price target on Revolution Medicines to $265 from a previous $225, reiterating a Buy rating. The bank's conviction is centered on the recent approval of daraxonrasib, marketed as Rasonque, for previously treated metastatic pancreatic ductal adenocarcinoma.

BofA highlighted the company's readiness for a U.S. launch. An expanded access program has already supplied the drug to physicians on behalf of more than 2,000 patients, a factor the bank believes will support rapid commercial uptake. Key details include:

• Pricing: Rasonque is priced at $39,800 per 30-day supply.
• Financial Position: The company holds a strong cash position of $3.9 billion to support commercialization and parallel clinical programs.

Sector-Wide Trends

Ad

The designation comes as the biotechnology industry continues to outperform the broader market. According to BofA, the SPDR S&P Biotech ETF (XBI) has gained 22.4% year-to-date, significantly outpacing the S&P 500's 11.4% return over the same period.

The investment bank observed a distinct shift in investor preference within the sector. Companies with positive clinical data or approaching significant trial readouts have generally seen stronger stock performance than commercial-stage firms focused on product launches. While a supportive capital environment continues to reward positive clinical results, BofA expects investors to apply greater scrutiny to the execution of new drug launches.

Pipeline and Analyst Outlook

BofA Securities views Revolution Medicines as having the "deepest clinical and commercial lead in RAS-targeted cancer therapies," with multiple opportunities to extend that advantage over the next 12 months. Upcoming catalysts include data from zoldonrasib combinations and elironrasib studies in non-small cell lung cancer.

Other Wall Street firms have also issued positive updates on the company. Morgan Stanley recently initiated coverage with an Overweight rating, while several other firms, including Needham, Guggenheim, and UBS, have also raised their price targets on RVMD.